Guy A. Van Hazel

3.8k citations

40 papers · 2.4k indexed · 1 hit paper · h-index 18

Impact in

Hepatology top 1%
- Hepatocellular Carcinoma Treatment and Prognosis
Oncology top 1%
- Colorectal Cancer Treatments and Studies
- Cancer Treatment and Pharmacology
- Colorectal Cancer Surgical Treatments
- Pancreatic and Hepatic Oncology Research

Papers in

Hepatology 13
- Hepatocellular Carcinoma Treatment and Prognosis 13
Oncology 31
- Colorectal Cancer Treatments and Studies 26
- Cancer Treatment and Pharmacology 11

Co-authors: Vladimir Moiseyenko Jana Prausová Paul Ruff Radek Lakomý Eric Van Cutsem David Ferry Josep Tabernero Carmen J. Allegra
Journals: Journal of Clinical Oncology (19 papers)European Journal of Cancer (3 papers)British Journal of Cancer (2 papers)BMC Cancer (2 papers)Annals of Oncology (2 papers)
Partner nations: Australia United States Belgium

In The Last Decade

Guy A. Van Hazel

37 papers receiving 2.4k citations

Hit Papers

align trajectories log scale

Addition of Aflibercept to Fluorouracil, Leucovorin, and Irinotecan Improves Survival in a Phase III Randomized Trial in Patients With Metastatic Colorectal Cancer Previously Treated With an Oxaliplatin-Based Regimen 2012 · 986 citations

Peers

Countries citing papers authored by Guy A. Van Hazel

Since Specialization

Citations

This map shows the geographic impact of Guy A. Van Hazel's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Guy A. Van Hazel with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Guy A. Van Hazel more than expected).

Fields of papers citing papers by Guy A. Van Hazel

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Guy A. Van Hazel. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Guy A. Van Hazel. The network helps show where Guy A. Van Hazel may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Guy A. Van Hazel, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Guy A. Van Hazel Line = papers co-authored together Guy A. Van Hazel links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	A Prospective, Cross-Sectional, Multicenter Study Evaluating a Multi-Target Blood Protein in Vitro Diagnostic Test for Colorectal Cancer Journal of Gastrointestinal Cancer ·Joubert Alarcón Ormaza, Guy A. Van Hazel, Andrew Sloss, Stephen Pianko, G. G. Z. Silva, I. Rohwedde, (unknown), JC Campbell, 林建南, J.A.A Brito, Trevor Lockett, B.S. Lamakhanova	2026	0
2	Cetuximab Alone or With Irinotecan for Resistant KRAS-, NRAS-, BRAF- and PIK3CA-wild-type Metastatic Colorectal Cancer: The AGITG Randomized Phase II ICECREAM Study Clinical Colorectal Cancer ·Jeremy Shapiro, Subotheni Thavaneswaran, Craig Underhill, Kristy Robledo, Christos S. Karapetis, Fiona Day, Louise Nott, Michael Jefford, Lorraine A. Chantrill, Nick Pavlakis, Niall C. Tebbutt, Timothy Price, Mustafa Khasraw, Guy A. Van Hazel, Paul Waring, Sabine Tejpar, John Simes, Val Gebski, Jayesh Desai, Eva Segelov	2018	8
3	Observed benefit and safety of aflibercept in elderly patients with metastatic colorectal cancer: An age-based analysis from the randomized placebo-controlled phase III VELOUR trial Journal of Geriatric Oncology ·Paul Ruff, Eric Van Cutsem, Radek Lakomý, Jana Prausová, Guy A. Van Hazel, Vladimir Moiseyenko, Karen Soussan-Lazard, 健一重見, E. Magherini, Teresa Macarulla, Demetris Papamichael	2017	29
4	REsect: Blinded assessment of amenability to potentially curative treatment of previously unresectable colorectal cancer liver metastases (CRC LM) after chemotherapy ± RadioEmbolization (SIRT) in the randomized SIRFLOX trial. Journal of Clinical Oncology ·Benjamin Garlipp, Peter Gibbs, Guy A. Van Hazel, Rohan Jeyarajah, Robert C.G. Martin, Christiane J. Bruns, Hauke Lang, Derek Manas, Giuseppe Maria Ettorre, Fernando Pardo, Vincent Donckier, Christoph Benckert, Thomas M. van Gulik, Diane Goèré, Michael R. Schoen, Johann Pratschke, Wolf O. Bechstein, Antonio Martínez-Cuesta, Alexandru Stefanof, Max Seidensticker	2017	11
5	O-019 SIRFLOX: Randomized trial comparing first-line mFOLFOX6 ± bevacizumab versus mFOLFOX6 + selective internal radiation therapy (SIRT) ± bevacizumab in patients with metastatic colorectal cancer (mCRC) – analysis by presence or absence of extra-hepatic metastases and bevacizumab treatment Annals of Oncology ·Guy A. Van Hazel, Volker Heinemann, Navesh Sharma, Michael Findlay, Jens Ricke, Marc Peeters, David Pérez, Bridget A. Robinson, A. H. Strickland, 优选, Julio César Millán Solarte, Hendrik Kroening, Ido Wolf, Vinod Ganju, Euan Walpole, Éveline Boucher, Thomas Tichler, Val Gebski, Mark Van Buskirk, Peter Gibbs	2015	0
6	Phase II trial of selective internal radiation therapy and systemic chemotherapy for liver-predominant metastases from pancreatic adenocarcinoma BMC Cancer ·Peter Gibbs, Jung-Whan Row, Lara Lipton, David Cade, Michael Tapner, David Price, G. Bower, Richard Dowling, Meir Lichtenstein, Guy A. Van Hazel	2015	12
7	Selective Internal Radiation Therapy (SIRT) with yttrium-90 resin microspheres plus standard systemic chemotherapy regimen of FOLFOX versus FOLFOX alone as first-line treatment of non-resectable liver metastases from colorectal cancer: the SIRFLOX study BMC Cancer ·(unknown), Peter Gibbs, Val Gebski, Mark Van Buskirk, Kenneth G. Thurston, David Cade, Guy A. Van Hazel	2014	41
8	Time course of safety and efficacy of aflibercept in combination with FOLFIRI in patients with metastatic colorectal cancer who progressed on previous oxaliplatin-based therapy European Journal of Cancer ·Paul Ruff, David Ferry, Radek Lakomý, Jana Prausová, Guy A. Van Hazel, Paulo M. Hoff, David Cunningham, Dirk Arnold, Hans‐Joachim Schmoll, Vladimir Moiseyenko, Joseph McKendrick, Albert J. ten Tije, Don Welsh, Pankaj Bhargava, Soazig Chevalier, Teresa Macarulla, Eric Van Cutsem	2014	20
9	Aflibercept versus placebo in combination with fluorouracil, leucovorin and irinotecan in the treatment of previously treated metastatic colorectal cancer: Prespecified subgroup analyses from the VELOUR trial European Journal of Cancer ·Josep Tabernero, Eric Van Cutsem, Radek Lakomý, Jana Prausová, Paul Ruff, Guy A. Van Hazel, Vladimir Moiseyenko, David Ferry, Joseph McKendrick, Karen Soussan-Lazard, Soazig Chevalier, Carmen J. Allegra	2013	159
10	PIK3CA, BRAF, and PTEN Status and Benefit from Cetuximab in the Treatment of Advanced Colorectal Cancer—Results from NCIC CTG/AGITG CO.17 Clinical Cancer Research ·Christos S. Karapetis, Derek J. Jonker, Manijeh Daneshmand, Jennifer Hanson, Christopher J. O’Callaghan, Celia Marginean, John Zalcberg, John Simes, Malcolm J. Moore, Niall C. Tebbutt, Timothy Price, Jeremy Shapiro, Nick Pavlakis, Peter Gibbs, Guy A. Van Hazel, M. Strauss, Rashida Haq, Shakeel Virk, Dongsheng Tu, Ian A.J. Lorimer	2013	128
11	Docetaxel plus cetuximab as second-line treatment for docetaxel-refractory oesophagogastric cancer: the AGITG ATTAX2 trial British Journal of Cancer ·(unknown), Niall C. Tebbutt, Halyna Reitii, Diana Zannino, A. H. Strickland, Guy A. Van Hazel, Nick Pavlakis, Vinod Ganju, J. Goldstein, Alexander Dobrovic, Val Gebski	2013	18
12	Addition of Aflibercept to Fluorouracil, Leucovorin, and Irinotecan Improves Survival in a Phase III Randomized Trial in Patients With Metastatic Colorectal Cancer Previously Treated With an Oxaliplatin-Based Regimen Journal of Clinical Oncology ·Eric Van Cutsem, Josep Tabernero, Radek Lakomý, Hans Prenen, Jana Prausová, Teresa Macarulla, Paul Ruff, Guy A. Van Hazel, Vladimir Moiseyenko, David Ferry, Joe McKendrick, Jonathan Polikoff, Alexia Tellier, R Castan, Carmen J. Allegra Hit paper breakdown →	2012	986
13	BRAF, PIK3CA, and PTEN status and benefit from cetuximab (CET) in the treatment of advanced colorectal cancer (CRC): Results from NCIC CTG/AGITG CO.17. Journal of Clinical Oncology ·Derek J. Jonker, Christos S. Karapetis, Christopher J. O’Callaghan, Celia Marginean, John Zalcberg, John Simes, Malcolm J. Moore, Niall C. Tebbutt, Timothy Price, Manijeh Daneshmand, Jennifer Hanson, Jeremy Shapiro, Nick Pavlakis, Peter Gibbs, Guy A. Van Hazel, S Nebelung, Rashida Haq, Shakeel Virk, Dongsheng Tu, Ian A.J. Lorimer	2012	2
14	Single-agent irinotecan or 5-fluorouracil and leucovorin (FOLFIRI) as second-line chemotherapy for advanced colorectal cancer; results of a randomised phase II study (DaVINCI) and meta-analysis European Journal of Cancer ·Stephen Clarke, Sonia Yip, Chris Brown, Guy A. Van Hazel, David Ransom, David Goldstein, Tetsuo Horie, Niall C. Tebbutt, Martin Buck, R. M. Lowenthal, 洋介星島, Val Gebski, John Zalcberg, R. J. Simes	2011	17
15	The GOFURTGO Study: AGITG Phase II Study of fixed dose rate gemcitabine–oxaliplatin integrated with concomitant 5FU and 3-D conformal radiotherapy for the treatment of localised pancreatic cancer British Journal of Cancer ·(unknown), David Goldstein, Nigel Spry, Michelle M. Cummins, Chris Brown, Guy A. Van Hazel, 周新伏, Sharon María González Herrera, Martin Borg, Stephen P. Ackland, Chris Wratten, Jeremy Shapiro, 朱正平, George Hruby, Lisa G. Horvath, Sean Bydder, Craig Underhill, Jennifer A. Harvey, Val Gebski	2011	12
16	Bevacizumab is equally effective and no more toxic in elderly patients with advanced colorectal cancer: a subgroup analysis from the AGITG MAX trial: an international randomised controlled trial of Capecitabine, Bevacizumab and Mitomycin C Annals of Oncology ·Timothy Price, Diana Zannino, Kate Wilson, R. J. Simes, J Cassidy, Guy A. Van Hazel, Bridget A. Robinson, A. Broad, Vinod Ganju, Stephen P. Ackland, Niall C. Tebbutt	2011	93
17	Capecitabine, Bevacizumab, and Mitomycin in First-Line Treatment of Metastatic Colorectal Cancer: Results of the Australasian Gastrointestinal Trials Group Randomized Phase III MAX Study Journal of Clinical Oncology ·Niall C. Tebbutt, Kate Wilson, Val Gebski, Michelle M. Cummins, Diana Zannino, Guy A. Van Hazel, Bridget A. Robinson, A. Broad, Vinod Ganju, Stephen P. Ackland, Garry Forgeson, David Cunningham, Mark Saunders, Martin R. Stockler, Sarah Landry, John Zalcberg, R. J. Simes, Timothy Price	2010	315
18	Treatment of Fluorouracil-Refractory Patients With Liver Metastases From Colorectal Cancer by Using Yttrium-90 Resin Microspheres Plus Concomitant Systemic Irinotecan Chemotherapy Journal of Clinical Oncology ·Guy A. Van Hazel, Nick Pavlakis, David Goldstein, Ian Olver, Michael Tapner, David Price, M Dewilde, Shun Shimodan, Monica A. Rossleigh, Kajal Kotia, George Casella	2009	112
19	A Phase II study of bosentan, a dual endothelin receptor antagonist, as monotherapy in patients with stage IV metastatic melanoma Investigational New Drugs ·Richard Kefford, Jane Beith, Guy A. Van Hazel, Michael Millward, James Trotter, David Wyld, Charles G. Birch, Revati Shreeniwas, A. Morganti, DanielaMartorano Pires Gomide, R.Tajiyeva, Oliver Nayler, Martine Clozel	2006	52
20	Selective internal radiation therapy (SIRT) for liver metastases with concomitant systemic oxaliplatin, 5-fluorouracil and folinic acid: A phase I/II dose escalation study Journal of Clinical Oncology ·Guy A. Van Hazel, D. A. Price, G. Bower, Zhongji Deng, Yu Liu, William P. Steward	2005	9

About Guy A. Van Hazel

Guy A. Van Hazel is a scholar working on Hepatology, Oncology, Toxicology, Pulmonary and Respiratory Medicine and Cancer Research, having authored 40 papers that have together received 2.4k indexed citations. Recurring topics across this work include Colorectal Cancer Treatments and Studies (26 papers), Hepatocellular Carcinoma Treatment and Prognosis (13 papers), Cancer Treatment and Pharmacology (11 papers), Gastric Cancer Management and Outcomes (10 papers), Radiomics and Machine Learning in Medical Imaging (5 papers), Cancer therapeutics and mechanisms (4 papers), Cancer Genomics and Diagnostics (4 papers) and Bioactive Compounds and Antitumor Agents (3 papers). The work is most often cited by research in Hepatology (909 citations), Oncology (1.9k citations), Pulmonary and Respiratory Medicine (913 citations), Pathology and Forensic Medicine (373 citations) and Cancer Research (294 citations). Guy A. Van Hazel has collaborated with scholars based in Australia, United States and Belgium. Frequent co-authors include Vladimir Moiseyenko, Jana Prausová, Paul Ruff, Radek Lakomý, Eric Van Cutsem, David Ferry, Josep Tabernero, Carmen J. Allegra, Teresa Macarulla and Joe McKendrick. Their work appears in journals such as Journal of Clinical Oncology, European Journal of Cancer, British Journal of Cancer, BMC Cancer and Annals of Oncology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact